WO2021252891A3 - In silico generated target lists - Google Patents

In silico generated target lists Download PDF

Info

Publication number
WO2021252891A3
WO2021252891A3 PCT/US2021/037004 US2021037004W WO2021252891A3 WO 2021252891 A3 WO2021252891 A3 WO 2021252891A3 US 2021037004 W US2021037004 W US 2021037004W WO 2021252891 A3 WO2021252891 A3 WO 2021252891A3
Authority
WO
WIPO (PCT)
Prior art keywords
dysfunctional
methods
cells
preferentially expressed
markers
Prior art date
Application number
PCT/US2021/037004
Other languages
French (fr)
Other versions
WO2021252891A2 (en
Inventor
Ronald Herbst
Yang Lee
Original Assignee
Pyxis Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyxis Oncology, Inc. filed Critical Pyxis Oncology, Inc.
Publication of WO2021252891A2 publication Critical patent/WO2021252891A2/en
Publication of WO2021252891A3 publication Critical patent/WO2021252891A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to methods for identifying gene targets by interrogating genes preferentially expressed with dysfunctional T cell markers, systems for generating an in silico target list preferentially expressed with dysfunctional T cell markers and with or without regulatory T cells (Treg) markers, methods of treating cancer by interrogating genes preferentially expressed with dysfunctional T cell markers and with or without Treg markers, methods of treating cancer by interrogating genes preferentially expressed by T effector cells and not by dysfunctional T cells or regulatory T cells (Tregs), and methods of treating autoimmune disease.
PCT/US2021/037004 2020-06-11 2021-06-11 In silico generated target lists WO2021252891A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063037687P 2020-06-11 2020-06-11
US63/037,687 2020-06-11
US202063040600P 2020-06-18 2020-06-18
US63/040,600 2020-06-18

Publications (2)

Publication Number Publication Date
WO2021252891A2 WO2021252891A2 (en) 2021-12-16
WO2021252891A3 true WO2021252891A3 (en) 2022-01-20

Family

ID=76744990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/037004 WO2021252891A2 (en) 2020-06-11 2021-06-11 In silico generated target lists

Country Status (1)

Country Link
WO (1) WO2021252891A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180100201A1 (en) * 2015-06-29 2018-04-12 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2018209324A2 (en) * 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180100201A1 (en) * 2015-06-29 2018-04-12 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
WO2018209324A2 (en) * 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

Also Published As

Publication number Publication date
WO2021252891A2 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
Geis et al. Silencing and transcriptional regulation of endogenous retroviruses: an overview
Akiyoshi et al. Evolutionary cell biology of chromosome segregation: insights from trypanosomes
van der Veeken et al. Natural genetic variation reveals key features of epigenetic and transcriptional memory in virus-specific CD8 T cells
Lubelsky et al. DNA replication and transcription programs respond to the same chromatin cues
WO2020219682A3 (en) Gene knock-outs to improve t cell function
JP2018082709A5 (en)
Alleva et al. Moving and stopping: Regulation of chromosome movement to promote meiotic chromosome pairing and synapsis
Graf et al. Pramel7 mediates ground-state pluripotency through proteasomal–epigenetic combined pathways
WO2019144126A8 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
Petsalaki et al. The abscission checkpoint: a guardian of chromosomal stability
MX2019014516A (en) Method for knocking out target gene in t cell in vitro and crrna used in the method.
Lewis et al. Building the class 2 CRISPR-Cas arsenal
Hatch et al. Chromothripsis
AU2024201649A1 (en) A fully-human T cell receptor specific for the 369-377 epitope derived from the HER2/Neu (ERBB2) receptor protein
WO2022120094A3 (en) Compositions and methods for the targeting of bcl11a
Wiebe et al. The barrier to autointegration factor: interlocking antiviral defense with genome maintenance
Tůmová et al. Structural organization of very small chromosomes: study on a single-celled evolutionary distant eukaryote Giardia intestinalis
Levy et al. dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region
Alshamsan et al. Prediction of Chlamydia pneumoniae protein localization in host mitochondria and cytoplasm and possible involvements in lung cancer etiology: a computational approach
Krause et al. MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR
Gong et al. R-loops at chromosome ends: from formation, regulation, and cellular consequence
Lavia et al. An epigenetic LINE-1-based mechanism in cancer
WO2021252891A3 (en) In silico generated target lists
Tieu et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
Hsieh et al. Tn7-CRISPR-Cas12K elements manage pathway choice using truncated repeat-spacer units to target tRNA attachment sites

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21737310

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21737310

Country of ref document: EP

Kind code of ref document: A2